1P-LSD

Product Description

1. Classification and Chemical Overview

1P-LSD (chemically designated as $(6aR,9R)\text{-4-propionyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide}$ or $1\text{-propionyl-lysergic acid diethylamide}$) is an unlicensed synthetic lysergamide derivative belonging to the ergoline chemical superclass. Structurally, it is a semi-synthetic analogue and $N^1\text{-acylated}$ prodrug of lysergic acid diethylamide (LSD-25). The core tetracyclic indoloquinoline skeleton corresponds to that of native lysergic acid diethylamide, with the indole nitrogen atom at position 1 substituted with an electron-withdrawing, lipophilic propionyl moiety ($\text{-CO-CH}_2\text{-CH}_3$). 1P-LSD possesses an empirical molecular formula of $\text{C}_{23}\text{H}_{29}\text{N}_{3}\text{O}_{2}$ and an average molecular mass of approximately $379.50\text{ g/mol}$.

Finished preparations circulating within underground recreational drug markets and grey-market “research chemical” distribution channels typically present as perforated absorbent paper blotters (each square tab containing microgram quantities, commonly standardized to $100\text{ mcg}$ or $150\text{ mcg}$ of 1P-LSD base or tartrate salt), micro-tablets (“pellets”), or liquid ethanolic/aqueous solutions intended for sublingual or oral ingestion.

Within the United Kingdom regulatory framework, 1P-LSD holds no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). It is not catalogued in the British National Formulary (BNF) and holds no therapeutic status as a Prescription Only Medicine (POM), Pharmacy (P) medicine, or General Sales List (GSL) drug under the Human Medicines Regulations 2012. Under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, 1P-LSD is categorized as a Class A, Schedule 1 controlled drug. While originally introduced in 2015 as a grey-market designer drug intended to exploit a legal loophole in early UK generic lysergamide definitions, the UK Home Office—acting on statutory advice from the Advisory Council on the Misuse of Drugs (ACMD)—amended the Misuse of Drugs Act 1971 to capture 1-alkylated and 1-acylated lysergamides (including 1P-LSD, ALD-52, and 1cP-LSD) under Class A control. Furthermore, its supply, production, and importation are unlawful under the Psychoactive Substances Act 2016. Commercial distribution occurs exclusively through dark-web platforms and illicit suppliers, posing acute clinical hazards regarding active microgram dosing inaccuracies, chemical degradation (epimerization into inactive iso-1P-LSD), and synthesis impurities.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of 1P-LSD is governed by its function as an $N^1\text{-acyl}$ prodrug that converts to lysergic acid diethylamide (LSD), alongside weak intrinsic receptor binding prior to complete deacylation:

• Metabolic Hydrolysis into Lysergic Acid Diethylamide (LSD): Preclinical pharmacodynamic and pharmacokinetic evaluations in vitro (human liver microsomes and human serum) and in vivo (rodent models) confirm that the propionyl group at the 1-position is enzymatically cleaved, hydrolysing 1P-LSD into free, active LSD. In rodent head-twitch response (HTR) assays, 1P-LSD produces behavioral responses identical to LSD, with a molar potency approximately $38\%$ that of parent LSD, consistent with bioavailability-dependent metabolic conversion.

• Potent Cortical $5\text{-HT}_{2\text{A}}$ Receptor Agonism: The generated systemic LSD binds as a high-affinity partial agonist at human postsynaptic serotonin $5\text{-HT}_{2\text{A}}$ receptors ($K_i \approx 2\text{ to }3\text{ nM}$) localized on the apical dendrites of glutamatergic pyramidal neurons in layer V of the cerebral cortex. Structural crystallographic models demonstrate that LSD becomes “trapped” within the orthosteric binding pocket of the $5\text{-HT}_{2\text{A}}$ receptor due to the formation of a conformational “lid” (extracellular loop 2 [EL2]), accounting for its sustained intracellular signaling. Receptor activation couples to the $G_{\alpha q/11}$ intracellular cascade, stimulating phospholipase C (PLC) and mobilizing inositol trisphosphate ($\text{IP}_3$) and intracellular calcium ($Ca^{2+}$). This triggers excessive glutamate release, alters thalamocortical gating, and decreases functional connectivity within the default mode network (DMN), driving profound perceptual distortions, ego dissolution, and synaesthesia.

• Non-Target Serotonergic, Dopaminergic, and Adrenergic Binding: Converted LSD exhibits broad, non-selective polypharmacology across the monoaminergic system:

  • High affinity for other central serotonin receptors, including $5\text{-HT}_{1\text{A}}$, $5\text{-HT}_{2\text{C}}$, $5\text{-HT}_6$, and $5\text{-HT}_7$.

  • Moderate-to-high affinity for dopamine $D_1$ and $D_2$ receptor families; direct $D_2$ receptor stimulation is responsible for the distinct cognitive stimulation, psychomotor drive, and alertness characteristic of lysergamides compared to classical tryptamines.

  • Agonism at trace amine-associated receptor 1 (TAAR1) and peripheral/central $\alpha_1$– and $\alpha_2$-adrenergic receptors, driving peripheral sympathomimetic outflow (mydriasis, vasoconstriction, tachycardia).

• Minimal Intrinsic Affinity of Intact 1P-LSD: Computational docking and in vitro binding assays demonstrate that the bulky 1-propionyl moiety sterically interferes with the hydrogen-bonding network within the $5\text{-HT}_{2\text{A}}$ binding pocket. Intact 1P-LSD possesses approximately 10- to 20-fold lower direct binding affinity for $5\text{-HT}_{2\text{A}}$ compared to LSD, indicating that its psychedelic pharmacology is overwhelmingly mediated by its active cleaved metabolite.

3. Approved UK Clinical Indications and Therapeutic Scope

1P-LSD possesses no approved clinical indications in the United Kingdom. No randomized, double-blind, multicentre Phase I–III clinical trials conforming to MHRA statutory criteria have ever evaluated 1P-LSD for human therapeutic safety, dosage tolerability, or clinical efficacy.

The National Institute for Health and Care Excellence (NICE) does not endorse, recommend, or integrate 1P-LSD into any clinical pathway. It is absent from guidelines governing major depressive disorder (NG222), anxiety disorders, post-traumatic stress disorder (PTSD), or substance use disorders. While pharmaceutical-grade synthetic LSD-25 and psilocybin have entered regulated academic research trials in specialized UK tertiary centres under strict Home Office Schedule 1 licenses, 1P-LSD has never received regulatory authorization or medicinal licensing.

The practical application of 1P-LSD is confined entirely to non-clinical illicit recreational drug abuse, unregulated online “psychedelic microdosing,” and underground psychedelic therapy. In these unauthorized settings, it is sought for:

• Replicating the subjective, therapeutic, or recreational profile of classical LSD using pre-dosed blotters (often perceived by consumers as offering more reliable microgram dosing than illicit black-market LSD tabs).

• Inducing intense acute psychedelic experiences lasting 8 to 12 hours, characterized by visual synthesis, mystical-type experiences, and cognitive introspection.

• Sub-perceptual “microdosing” regimens ($10\text{ to }20\text{ mcg}$ taken every third day) intended to enhance creativity, cognitive focus, and emotional resilience in workplace or academic settings.

1P-LSD holds no status within the NHS drug tariff, cannot be prescribed on NHS prescription forms (FP10), and must never be procured or administered for human medical treatment.

4. Pharmacokinetic Profile and Metabolic Fate

Because 1P-LSD is typically administered sublingually or orally via blotter paper, its pharmacokinetic disposition reflects rapid mucosal or gastrointestinal absorption, bioactivation to LSD, and multi-phasic hepatic elimination:

• Absorption: Following oral or sublingual administration of blotter paper, 1P-LSD is rapidly absorbed across the oral mucosa and upper gastrointestinal tract. The subjective onset of psychoactive effects is observed within 30 to 60 minutes post-ingestion (slightly delayed relative to intravenous or free LSD due to the required chemical or enzymatic deacylation step), achieving peak systemic plasma concentrations ($T_{max}$) of converted LSD between 90 and 150 minutes. Absolute systemic bioavailability via the oral route is estimated at $>70\%$.

• Distribution: Both intact 1P-LSD and its metabolite LSD distribute rapidly into systemic tissues. Unconjugated LSD displays high lipophilicity, freely traversing the blood-brain barrier (BBB) to occupy neocortical $5\text{-HT}_{2\text{A}}$ receptors. Systemic plasma protein binding of LSD in humans is moderate (approximately $65\text{ to }80\%$), binding predominantly to human serum albumin. The apparent volume of distribution ($V_d$) of the active metabolite is extensive, averaging $0.28\text{ to }0.4\text{ L/kg}$.

• Biotransformation: In vivo clearance involves rapid, ubiquitous deacylation followed by classical hepatic lysergamide catabolism:

  • Enzymatic Deacylation (Bioactivation): Non-specific carboxylesterases (CES) and amidases in the gastrointestinal mucosa, liver microsomes, and systemic circulation cleave the 1-propionyl group, converting 1P-LSD into free LSD and propionic acid.

  • Hepatic Cytochrome P450 Metabolism: Liberated LSD is extensively metabolized in the liver by cytochrome P450 isoenzymes (primarily CYP3A4 and CYP2D6). The major metabolic pathway yields 2-oxo-3-hydroxy-LSD (O-H-LSD), an inactive metabolite present in human urine at concentrations 16 to 40 times higher than parent LSD. Secondary pathways include N-demethylation (yielding nor-LSD) and aromatic mono-hydroxylation.

• Elimination: Systemic elimination of metabolites occurs predominantly via renal excretion. Less than $1\%$ of an administered dose is excreted as unchanged LSD in the urine, with the vast majority cleared as polar glucuronide conjugates, 2-oxo-3-hydroxy-LSD, and trace nor-LSD. The terminal plasma elimination half-life ($t_{1/2}$) of converted LSD in humans is approximately 3.6 to 5 hours. However, due to conformational receptor trapping at the $5\text{-HT}_{2\text{A}}$ site, pharmacodynamic effects persist far beyond plasma clearance, yielding a total subjective trip duration of 8 to 12 hours, with residual sleep disturbances and psychological fatiguability lasting up to 24 hours.

5. Physiological Effects and Adverse Event Spectrum

The primary physiological effect reported in non-clinical contexts is profound central sensory alterations (visual pseudohallucinations, geometric patterning, intensified color perception, time dilation), cognitive restructuring, ego dissolution, and mood volatility. However, robust stimulation of central monoaminergic and peripheral sympathomimetic pathways generates a distinct spectrum of multi-system adverse effects:

• Neuropsychiatric Disturbances (Common to Very Common, $\ge 1/100$ to $\ge 1/10$):

  • Acute panic reactions, severe anxiety, terror, and paranoid delusions (the classical “bad trip”), which can lead to erratic, dangerous flight behaviors.

  • Depersonalization, derealization, loss of reality testing, and transient substance-induced psychosis.

  • Hallucinogen Persisting Perception Disorder (HPPD): prolonged or permanent re-emergence of geometric visual distortions, visual trails (palinopsia), “visual snow,” and afterimages persisting months or years after cessation.

  • Precipitation of major psychiatric illness: acute unmasking or acceleration of underlying psychotic illness (schizophrenia) or bipolar manic episodes in vulnerable individuals.

• Autonomic and Sympathomimetic Dysregulation (Common, $1/100$ to $<1/10$):

  • Marked bilateral pupillary dilation (mydriasis) and severe photophobia.

  • Moderate sinus tachycardia, palpitations, and transient elevations in systolic and diastolic blood pressure.

  • Cutaneous piloerection (“goosebumps”), profuse diaphoresis, and fine peripheral resting tremors.

  • Transient peripheral vasoconstriction: sensations of cold extremities and mild Raynaud’s-like pallor.

• Gastrointestinal and Somatic Symptoms (Common, $1/100$ to $<1/10$):

  • Nausea, gastric churning, dry heaving, and transient emesis (provoked by peripheral $5\text{-HT}_3$ and $5\text{-HT}_2$ stimulation).

  • Muscular tension, jaw clenching (bruxism), and neck stiffness.

• Severe, Emergent and Life-Threatening Hazards (Rare to Toxicological Overdose):

  • Accidental Physical Trauma and Behavioral Fatalities: Profound loss of danger awareness and sensory distortion can result in fatal misadventures (e.g., falls from heights, pedestrian motor vehicle collisions, or severe accidental hypothermia).

  • Serotonin Toxicity (Serotonin Syndrome): Concomitant ingestion with monoamine oxidase inhibitors (MAOIs), serotonergic antidepressants, or sympathomimetic stimulants exponentially elevates central serotonergic tone, precipitating life-threatening hyperthermia ($>39.0^\circ\text{C}$), neuromuscular clonus, hyperreflexia, autonomic instability, and rhabdomyolysis.

  • Risks of Unregulated Research Chemicals: Blotter papers sold as “1P-LSD” carry severe risks of mislabeling or substitution with far more dangerous, non-lysergamide compounds, such as synthetic NBOMe derivatives (e.g., 25I-NBOMe) or DOx compounds. NBOMe analogues act as full $5\text{-HT}_{2\text{A}}$ agonists and frequently induce fatal tonic-clonic seizures, cardiac arrest, malignant hyperthermia, and renal failure at microgram doses.

6. Contraindications, Drug Interactions, and Clinical Precautions

Given its non-approved status, potent central psychedelic pharmacology, and Class A legal scheduling, 1P-LSD requires strict adherence to pharmacological contraindications and emergency harm-minimisation standards:

• Contraindications:

  • Absolute Contraindication in All Humans: The compound is an unregulated, illicit Class A substance lacking medicinal safety clearance.

  • Personal or Family History of Psychosis: Absolute contraindication in patients with schizophrenia, schizoaffective disorder, bipolar I disorder, or a first-degree family history of primary psychotic disorders.

  • Cardiovascular Disease: Contraindicated in active coronary artery disease, history of myocardial infarction, cardiac arrhythmias, or uncontrolled hypertension ($>140/90\text{ mmHg}$), as sympathomimetic outflow accelerates myocardial oxygen demand.

  • Concurrent Monoamine Oxidase Inhibitors (MAOIs): Absolute contraindication with pharmaceutical MAOIs (e.g., phenelzine, tranylcypromine, moclobemide) or botanical harmala alkaloids.

  • Pregnancy and Lactation: Absolute contraindication; lysergamides possess intrinsic oxytocic and uterine-contracting properties that can precipitate spontaneous abortion or preterm labour; human embryotoxic and teratogenic profiles are completely uncharacterized.

  • Paediatric Population: Absolute contraindication in individuals under 18 years of age.

• Drug Interactions:

  • Lithium Pharmacotherapy: Absolute contraindication. Co-administration of classical psychedelics (lysergamides, tryptamines) with lithium carries documented clinical risks of precipitating severe, life-threatening grand mal seizures, status epilepticus, and profound comatose encephalopathy.

  • Serotonergic Antidepressants (SSRIs, SNRIs, TCAs): Chronic SSRI/SNRI administration downregulates central $5\text{-HT}_{2\text{A}}$ receptors, significantly attenuating the psychedelic effects of lysergamides. This frequently prompts users to ingest massive, supratherapeutic doses, elevating the risk of peripheral toxicity and autonomic instability.

  • Central Nervous System Stimulants (e.g., MDMA, Cocaine, Amfetamines): Synergistic adrenergic overdrive, substantially increasing the incidence of panic attacks, malignant hypertension, tachycardia, hyperthermia, and cardiac dysrhythmias.

  • Tramadol and Bupropion: Lowers seizure thresholds, substantially increasing the risk of drug-induced epileptiform activity during peak lysergamide intoxication.

• Clinical Precautions and Harm Minimisation:

  • Acute Emergency Management (“Red Flags”): Individuals presenting to NHS emergency departments with severe agitation, hyperthermia, sustained tachycardia, or violent delirium following 1P-LSD ingestion require immediate emergency medical care (999/A&E). First-line clinical interventions include:

    • De-escalation in a quiet, darkened, low-stimulus environment with continuous calm reassurance (“talking down”).

    • Parenteral benzodiazepines (e.g., intravenous diazepam $5\text{ to }10\text{ mg}$ or lorazepam $1\text{ to }2\text{ mg}$) as the first-line pharmacological treatment for psychomotor agitation, panic, and hypertension. Antipsychotics (e.g., haloperidol) should be used with extreme caution due to risks of lowering seizure thresholds and worsening QTc prolongation.

    • Active external cooling protocols in patients exhibiting hyperthermia.

  • Toxicological and Analytical Awareness: Standard automated NHS urine toxicology immunoassay screens (UDS) typically do not detect 1P-LSD or LSD due to the minute microgram dosing quantities. Specialized high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) targeting LSD and its metabolite 2-oxo-3-hydroxy-LSD is required for analytical confirmation. Clinical diagnosis must be established based on the clinical toxidrome (mydriasis, visual alterations, psychomotor agitation, tachycardia).

  • Product Warning and Adulteration Counseling: Healthcare professionals encountering individuals who report purchasing unregulated 1P-LSD online must educate them on the absence of human safety data, legal Class A penalties, and the critical danger of NBOMe blotter substitution, which carries severe risks of fatal toxicity.

Additional Information